Latest Insider Transactions at Rayze Bio, Inc. (RYZB)
This section provides a real-time view of insider transactions for Rayze Bio, Inc. (RYZB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RayzeBio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RayzeBio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 26
2024
|
Viking Global Investors LP |
SELL
Other acquisition or disposition
|
Indirect |
13,285,400
-100.0%
|
-
|
|
Feb 26
2024
|
Richard A. Heyman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
367,446
-100.0%
|
$22,781,652
$62.5 P/Share
|
|
Feb 26
2024
|
Maha Katabi |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,419,528
-100.0%
|
$150,010,736
$62.5 P/Share
|
|
Feb 26
2024
|
Susan Moran CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
323,455
-100.0%
|
$20,054,210
$62.5 P/Share
|
|
Feb 26
2024
|
Kenneth Song PRESIDENT AND CHIEF EXECUTIVE |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,622,968
-100.0%
|
$100,624,016
$62.5 P/Share
|
|
Feb 26
2024
|
Arvind Kush CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
78,433
-100.0%
|
$4,862,846
$62.5 P/Share
|
|
Jan 22
2024
|
Susan Moran CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,875
+8.73%
|
$92,625
$3.24 P/Share
|
|
Sep 19
2023
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,857,706
+32.61%
|
-
|
|
Sep 19
2023
|
Maha Katabi |
BUY
Open market or private purchase
|
Indirect |
472,222
+16.33%
|
$8,499,996
$18.0 P/Share
|
|
Sep 19
2023
|
Maha Katabi |
BUY
Conversion of derivative security
|
Indirect |
1,947,306
+50.0%
|
-
|
|
Sep 19
2023
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
2,777,778
+18.39%
|
$50,000,004
$18.0 P/Share
|
|
Sep 19
2023
|
Viking Global Investors LP |
BUY
Conversion of derivative security
|
Indirect |
10,507,622
+41.59%
|
-
|
|
Sep 19
2023
|
Ven Bio Global Strategic Fund Iii, L.P. |
BUY
Conversion of derivative security
|
Direct |
5,158,162
+24.4%
|
-
|
|
Sep 19
2023
|
Wellington Biomedical Innovation Master Investors (Cayman) Ii L.P. |
BUY
Conversion of derivative security
|
Direct |
1,557,846
+50.0%
|
-
|